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The short chain fatty acid receptor FFA2 is able to stimulate
signaling via both Gi- and Gq/G11-promoted pathways. These
pathways are believed to control distinct physiological end
points but FFA2 receptor ligands appropriate to test this
hypothesis have been lacking. Herein, we characterize
AZ1729, a novel FFA2 regulator that acts as a direct allosteric
agonist and as a positive allosteric modulator, increasing the
activity of the endogenously produced short chain fatty acid
propionate in Gi-mediated pathways, but not at those trans-
duced by Gq/G11. Using AZ1729 in combination with direct
inhibitors of Gi and Gq/G11 family G proteins demonstrated
that although both arms contribute to propionate-mediated
regulation of phospho-ERK1/2 MAP kinase signaling in
FFA2-expressing 293 cells, the Gq/G11-mediated pathway is
predominant. We extend these studies by employing AZ1729
to dissect physiological FFA2 signaling pathways. The capac-
ity of AZ1729 to act at FFA2 receptors to inhibit -adrenore-
ceptor agonist-promoted lipolysis in primary mouse adi-
pocytes and to promote chemotaxis of isolated human
neutrophils confirmed these as FFA2 processes mediated by
Gi signaling, whereas, in concert with blockade by the Gq/G11
inhibitor FR900359, the inability of AZ1729 to mimic or reg-
ulate propionate-mediated release of GLP-1 from mouse
colonic preparations defined this physiological response as
an end point transduced via activation of Gq/G11.
Short chain fatty acids (SCFAs)2 are carboxylic acids contain-
ing 1 to 6 carbons. These are produced in the body predomi-
nantly by the fermentation of non-digestible carbohydrates
(fibers) through the metabolic activity of the gut microbiota,
with acetate (C2), propionate (C3), and butyrate (C4) being the
most abundant products (1, 2). Until recently, the role of SCFAs
was believed to be confined to providing either a source of
energy or as intermediate products of more complexmolecules
(1). For example, colonocytes utilize C4 as a main energy sup-
ply, whereas the liver can source C2 as a substrate for the syn-
thesis of cholesterol or longer chain fatty acids and C3 as a
precursor for gluconeogenesis (2). However, with the discovery
and de-orphanization of a pair of G protein-coupled receptors
(GPCRs) responsive to SCFAs, FFA2, and FFA3 (previously
designatedGPR43 andGPR41, respectively) (3), it became clear
that the SCFAs also act as signalingmolecules (4–6). The SCFA
receptors are mainly expressed in tissues involved in metabolic
regulation, in particular white adipose tissue, intestinal
enteroendocrine cells, and pancreatic beta cells (7) and in
immune cells (8). Hence, a role for the SCFA receptors, in par-
ticular FFA2, in controlling energy homeostasis, and potentially
in the regulation of metabolic disorders, has been proposed
(9–11).
Despite the increasing interest surrounding SCFA receptors,
a general paucity of selective ligands has rendered the study and
understanding of their pathophysiological functions extremely
challenging (7, 12). For example, although there is a rank order
of selectivity of endogenous SCFAs for the receptors (13), with
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C2 being more potent at human FFA2 than at FFA3, this level of
selectivity, in concertwith thegeneral lowpotencyof theSCFAs, is
insufficient to allow their use in defining physiological roles of
FFA2 over FFA3 without additional studies that incorporate
receptor knock-down or knock-out models (7). Moreover, even
this poor degree of SCFA ligand selectivity is absent in the mouse
orthologs of the SCFA receptors, where C2 is equipotent in acti-
vating FFA2 and FFA3 (7, 14). To date only a small number of
selective synthetic ligands have been identified, with “compound
1” (3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-
yl)amino)-4-oxobutanoic acid) and 4-CMTB (4-chloro--(1-
methylethyl)-N-2-thiazolyl-benzeneacetamide) being the best
characterized ligands with agonist activity at FFA2 (7, 12).
Although compound 1 is a selective and relatively potent
orthosteric agonist at both human and mouse FFA2 (15), other
representatives from this chemical series display markedly
lower potency at murine FFA2 (15), limiting their potential for
studies in murine cells and tissues (7). Equally, although
4-CMTB acts as both a direct allosteric agonist and also as a
positive allosteric modulator (PAM) of the action of SCFAs at
human FFA2 (16–19), and displays similar activity at mouse
FFA2, the poor pharmacokinetic properties of this ligand (17)
have limited its use within in vivo validation studies for FFA2.
An interesting feature of FFA2 is that, unlike the closely
related SCFA receptor FFA3, which signals only via Gi-family G
proteins, it is able to initiate signals via both Gi and Gq/G11-
mediated pathways (7, 13). However, the contribution of these
two signaling arms to various downstream cascades and,
indeed, to physiological processes remains, in large part, unde-
fined. Clearly, mechanistically distinct and potent classes of
synthetic ligands are required to define such questions. To
begin to address this need, herein, we characterize a novel syn-
thetic ligand N-[3-(2-carbamimidamido-4-methyl-1,3-thiazol-
5-yl)phenyl]-4-fluorobenzamide (AZ1729). We demonstrate
thatAZ1729 acts as a FFA2 allosteric agonist andPAMby selec-
tively activating Gi signaling but lacks the capacity to activate
FFA2 Gq/G11-mediated signaling pathways. In this way we
define AZ1729 as a Gi-biased ligand. In conjunction with the
use of selective inhibitors of the Gi and Gq/G11 classes of G
proteins, we then employ AZ1729 to define the relative contri-
bution of these pathways to the integration of ERK1/2-MAP
kinase activity in transfected cells and in natively expressing
systems, in whichwe show that both FFA2-mediated inhibition
of lipolysis and promotion of neutrophil chemotaxis reflect sig-
naling via Gi family G proteins. By contrast, in murine colonic
crypts FFA2 signaling to promote release of glucagon-like pep-
tide-1 (GLP-1) is not modulated by AZ1729 indicating that this
response proceeds via activation of Gq/G11.
Results
AZ1729 Activates FFA2-dependent Gi Signaling—In Flp-InTM
T-RExTM 293 cells (20) able to express human (h)FFA2-eYFP
only upon addition of the antibiotic doxycycline, the physiolog-
ical FFA2 receptor agonist propionate (C3) (Fig. 1A) inhibited
forskolin-stimulated cAMP levels in a concentration-depen-
dentmanner (pEC50 3.95 0.13) (Fig. 1B). AZ1729 (Fig. 1A),
which was identified initially as a regulator of FFA2 in a high
throughput screen conducted using an integrative, function
agnostic, dynamic mass redistribution assay, also inhibited for-
skolin-stimulated cAMP levels in these cells and, equally, did so
in a concentration-dependent manner (pEC50  6.90  0.14)
(Fig. 1B). AZ1729 was somewhat more efficacious in this assay
than C3 (74.0  3.1% and 61.1  2.8% inhibition of forskolin-
stimulated cAMP levels, respectively) and also more than 500-
foldmore potent (p 0.01). By contrast, a previously described
allosteric agonist of this receptor 4-CMTB (16, 18) (Fig. 1A),
although also able to inhibit forskolin-stimulated cAMP levels
(pEC50  5.88  0.39) was clearly a partial agonist (Fig. 1B).
These effects were dependent on the presence of hFFA2 as
none of C3, AZ1729, and 4-CMTB affected cAMP levels in
these cells when expression of the hFFA2 receptor was not
induced (Fig. 1C). As anticipated, this effect of each ligand was
transduced via pertussis toxin (PTX)-sensitiveGi-familyG pro-
teins. Treatment of doxycycline-induced cells with PTX, to
cause ADP-ribosylation of the  subunit of members of this G
protein subgroup, eliminated ligand regulation of cAMP levels
in each case (Fig. 1D). The ability of AZ1729 to induce Gi-me-
diated FFA2 signaling was also assessed in [35S]GTPS binding
assays, an end point that is best suited to, and usually reflects,
the contribution of Gi family G proteins (21). In membranes
prepared from Flp-InTM T-RExTM 293 cells induced to express
hFFA2-eYFP, AZ1729 was able to produce stimulation of
[35S]GTPS binding with pEC50 7.23  0.20 (Fig. 1E). Again,
this compound displayed potency that was significantly higher
than both C3 (pEC50 4.35  0.14, p  0.01) and 4-CMTB
(pEC50 6.50  0.16, p  0.05), although in this case without
marked differences in ligand efficacy (Fig. 1E).
AZ1729 Displays Gi-functional Bias at FFA2—As well as
transducing signals via “Gi” the FFA2 receptor is appreciated to
be able to also interact with, and signal via, Gq/11 G proteins
(4–6). Indeed, in cells induced to express hFFA2-eYFP, C3 pro-
duced a large increase in inositol monophosphate (IP1) accu-
mulation (Fig. 2A), with potency (pEC50 4.19 0.10) akin to
that observed in the cAMP regulation experiments. Although
4-CMTB also produced a partial effect in this assay (pEC50 
5.60 0.11), AZ1729was completely inactive at concentrations
up to the highest (30 M) that could be tested (Fig. 2A). These
observations indicated thatAZ1729might be a “Gi-biased” ago-
nist at hFFA2. To assess this hypothesis we also explored ligand
regulation of phospho-ERK1/2, production of which can be
induced by both Gi- and Gq/11-mediated signaling. C3 pro-
duced a robust increase of phospho-ERK1/2 levels (Fig. 2B)
with potency (pEC50 3.93 0.13) similar to those displayed
in bothGi- andGq/11-dependent assays. Interestingly, the effect
of C3 on the phosphorylation of ERK1/2 was partially inhibited
by pre-treatment of the cells with PTX and greatly reduced by
the Gq/G11 inhibitor FR900359 (22) (Fig. 2B), suggesting that
although C3mediates phospho-ERK1/2 accumulation via both
Gprotein classes it ismainly throughGq/G11. In the same assay,
AZ1729 was only a very weak partial agonist at this end point
(Fig. 2, C and D) and also displayed more modest potency
(pEC50  5.66  0.21). Interestingly, the effect of AZ1729 on
phospho-ERK1/2 accumulation was completely abolished in
hFFA2 cells pre-treated with PTX, but unaffected by treatment
with FR900359 (Fig. 2, C and D). The effects of both C3 and
AZ1729were completely abrogated uponpre-treatment of cells
Ligand Bias at Free Fatty Acid 2 Receptor
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with both PTX and FR900359 (Fig. 2, B–D). Together, these
data indicate thatAZ1729 behaves as a biased agonist at hFFA2;
preferentially activating Gi but being unable to engage with
Gq/G11 signaling.
AZ1729 Does Not Interact with the Orthosteric Binding Site
of FFA2—Synthetic agonists at FFA2 that share the same
orthosteric binding site as C3, and the other endogenously pro-
duced SCFAs, all contain a carboxylate group and this is inte-
gral to their agonist function (14, 15, 23, 24). AZ1729 does not,
and neither does it contain a bioisostere that might substitute
for the carboxylate (Fig. 1A). We examined, therefore, if
AZ1729 acted as an orthosteric agonist. This was assessed in
two distinct ways. First, we examined whether the Gi-mediated
agonism of AZ1729 was preserved in orthosteric binding site
mutants of hFFA2. Two arginine residues, Arg-180 and Arg-
255 (Ballesteros and Weinstein residue location numbers 5.39
and 7.35, respectively) act to coordinate the carboxylate moiety
of FFA2 orthosteric agonists (23). Mutation of either of these
residues to Ala was able to eliminate the ability of C3 to inhibit
forskolin-stimulated cAMP production (Fig. 3A) but did not
affect substantially the function of AZ1729 (Fig. 3B).Moreover,
as described previously (18), this was also the case for the allos-
-10 -9 -8 -7 -6 -5 -4 -3 -2
-20
0
20
40
60
80
100  C3
AZ1729
4-CMTB
Log  [Ligand]
%
 In
hi
bi
tio
n 
of
 c
AM
P 
pr
od
uc
tio
n
-10 -9 -8 -7 -6 -5 -4 -3 -2
-20
0
20
40
60
80
100 C3
4-CMTB
AZ1729
Log  [Ligand]
%
 S
tim
ul
at
io
n 
of
 [3
5 S
]G
TP
γS
O
OH
CH3
Cl
CH3 CH3
O
NHS
N
S
N
N
O
ClCl O
OH
NH
O
S
N
CH3
N
NH2
NH2
F
Propionate (C3) AZ1729
Compound 1 4-CMTB
A
B C
D E
-10 -9 -8 -7 -6 -5 -4 -3 -2
-20
0
20
40
60
80
100  C3
AZ1729
4-CMTB
Log  [Ligand]
%
 In
hi
bi
tio
n 
of
 c
AM
P 
pr
od
uc
tio
n
-10 -9 -8 -7 -6 -5 -4 -3 -2
-20
0
20
40
60
80
100  C3
AZ1729
4-CMTB
Log  [Ligand]
%
 In
hi
bi
tio
n 
of
 c
AM
P 
pr
od
uc
tio
n
FIGURE 1. AZ1729 is a potent activator of Gi-dependent FFA2 signaling. Chemical structures of C3, AZ1729, compound 1, and 4-CMTB are shown (A). The
effect of C3, 4-CMTB, and AZ1729 on forskolin-induced stimulation of cAMP production in Flp-InTM T-RExTM 293 cells that had been induced to express hFFA2
(B) or such cells thatwerepre-treatedwithPTX (D) is shown.Compoundeffects requirehFFA2aswithout inductionof the receptor no responseswereobserved
(C). The effect of C3, 4-CMTB, andAZ1729on [35S]GTPS incorporation inmembranes of hFFA2expressing cells (E). Data are expressed as percentage inhibition
of forskolin-stimulated cAMP production (B–D) or percent stimulation of [35S]GTPS binding (E). Results represent mean S.E. (n 9–12).
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teric agonist 4-CMTB (Fig. 3C). These data indicate that nei-
ther AZ1729 nor 4-CMTB interact with the arginine residues
that are the core of the FFA2 orthosteric binding pocket (23)
and are, therefore, allosteric agonists. Second, we performed
sets of radioligand binding experiments. [3H]GLPG0974 was
recently reported as an orthosteric radiolabeled antagonist of
-10 -9 -8 -7 -6 -5 -4 -3 -2
-20
0
20
40
60
80
100
120  C3
AZ1729
4-CMTB
Log  [Ligand]
IP
1 
(%
 o
f C
3)
A
-8 -7 -6 -5 -4 -3 -2
0
2000
4000
6000
8000
10000
PTX
FR900359
Control
PTX+FR900359
Log [C3]
ph
os
ph
o-
ER
K
1/
2
B
-10 -9 -8 -7 -6 -5 -4
0
2000
4000
6000
8000
10000
PTX
FR900359
Control
PTX+FR900359
Log [AZ1729]
ph
os
ph
o-
ER
K
1/
2
C
-10 -9 -8 -7 -6 -5 -4
-25
0
25
50
75
100
125
150
PTX
FR900359
Control
PTX+FR900359
Log [AZ1729]
ph
os
ph
o-
ER
K
1/
2 
(%
 o
f C
on
tr
ol
)
D
FIGURE 2. AZ1729 is a Gi-biased regulator of FFA2. The effect of C3,
4-CMTB, and AZ1729 on IP1 accumulation assay in Flp-In
TM T-RExTM 293 cells,
induced to express hFFA2, is shown (A). The effect of C3 (B) andAZ1729 (C) on
ERK1/2 phosphorylation in Flp-InTM T-RExTM 293 cells induced to express
hFFA2 that had been pre-treated or not with PTX and/or FR900359. Data are
expressed as the percentage of IP1 accumulation taking as 100% themaximal
effect of C3 (A), or ERK1/2 phosphorylation signal ratio between 665 and 620
nm multiplied by a factor of 10,000 (B and C). D, displays the same data as C
but presents the information% of themaximal effect of AZ1729 in untreated
FFA2 expressing cells (control). Results represent mean S.E. (n 6–8).
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FIGURE 3. AZ1729 signaling via FFA2 is not affected by mutations in the
orthosteric binding pocket. The effect of C3 (A), AZ1729 (B), and 4-CMTB (C)
on forskolin-induced stimulation of cAMPproduction in Flp-InTM T-RExTM 293
cells that hadbeen induced to expresswild type, R180Aor R255Amutants for
hFFA2. Data are expressed as the percentage inhibition of cAMP production.
Results represent the mean S.E. (n 6).
Ligand Bias at Free Fatty Acid 2 Receptor
18918 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 36•SEPTEMBER 2, 2016
 at G
lasgow
 U
niversity Library on D
ecem
ber 22, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
hFFA2 (25). In membranes from Flp-InTM T-RExTM 293 cells
induced to express hFFA2, [3H]GLPG0974 bound with high
affinity (Kd  7.5 nM) (25) and this was fully outcompeted by
increasing concentrations of C3 (pKi  2.78  0.11) (Fig. 4A).
This was also the case when using the previously described
hFFA2 receptor synthetic orthosteric agonist compound 1 (15)
(Fig. 1A) (pKi  6.58  0.09) (Fig. 4A). However, AZ1729 was
unable to compete fully with [3H]GLPG0974 for binding to the
receptor (Fig. 4A), demonstrating that AZ1729 does not share
an overlapping binding site with the radiolabeled antagonist. It
did, however, producemaximally 16.7 4.4% reduction in spe-
cific binding of this radioligand with apparent pKi  6.77 
0.50 (Fig. 4A). 4-CMTB was also poor in capacity to compete
with [3H]GLPG0974,maximally preventing only 10.9 6.8% of
the specific binding of this ligand with apparent pKi estimated
as 6.64 1.29 (Fig. 4A).
AZ1729 Interacts with a FFA2 Allosteric Binding Site—The
unaltered functional effect of AZ1729 at orthosteric binding
site mutants of hFFA2, and also the inability of this compound
to fully displace [3H]GLPG0974, raised the possibility that
AZ1729 might interact with an allosteric binding site on
hFFA2. To test this hypothesis we performed a three-way
radioligand binding equilibrium experiment (26). In particular,
we assessed the ability of 4-CMTB andAZ1729 tomodulate the
inhibition of [3H]GLPG0974 binding by the endogenous
orthosteric agonist, C3. Increasing concentrations of 4-CMTB
produced a leftward shift of the C3 concentration-response
curve, indicating that 4-CMTB increases the affinity of C3 to
inhibit [3H]GLPG0974 binding (Fig. 4B). Similar results were
obtained with AZ1729, although this compound, in addition to
a leftward shift of the C3 concentration-response curve, pro-
duced a downward shift (Fig. 4C) as anticipated from the mod-
est but detectable capacity of AZ1729 to directly modulate
binding of [3H]GLPG0974.Using an extended allosteric ternary
complex model equation (see “Materials and Methods”), we
quantified the affinity cooperativity factor of 4-CMTB and
AZ1729 versus [3H]GLPG0974 () and C3 (). This showed
that 4-CMTB did not have a significant cooperativity effect
toward [3H]GLPG0974 binding (  0.93, i.e. close to unity),
whereas AZ1729 displayed a weak negative cooperativity effect
(  0.67). In contrast, both 4-CMTB and AZ1729 displayed
positive cooperativity for C3 binding (  4.45  1.16 and
4.27 1.17, respectively). From the same equation it was pos-
sible to calculate the affinity of these synthetic compounds for
hFFA2 (pKB  6.52  0.17 for 4-CMTB and 6.84  0.11
for AZ1729). Together, these data indicate that AZ1729, as for
4-CMTB, binds to a FFA2 allosteric binding site.
AZ1729 Is a Functional Positive Allosteric Modulator in
FFA2-mediated Gi Signaling—Having established that AZ1729
displays positive cooperativity toward the binding of C3 to
hFFA2, we investigated whether this property would also be
observed in functional assays. 4-CMTBhas been reported to act
as both a direct agonist of the FFA2 receptor and also as an
effective PAMof the activity of C3 (16, 18). This was confirmed
in cAMPassays in cells induced to express hFFA2where, aswell
as acting directly as a partial agonist, 4-CMTB also increased, in
a concentration-dependent fashion, the observed potency of
C3 (Fig. 5A). Application of allosteric parameter fitting models
allowed estimation of the affinity (pKB) of 4-CMTB as 5.68 
0.17 and with the ligand displaying strong positive net cooper-
ativity (  28.35). In the same assay AZ1729 displayed very
strong positive net cooperativity versus C3, with   85.22.
Because AZ1729 effects on affinity of C3 weremodest (i.e.  
4.27  1.17) the functional cooperativity of AZ1729 observed
here in the C3 cAMP response can be largely attributed to
enhanced efficacy of C3 in the presence of AZ1729. Estimated
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FIGURE 4. AZ1729 is a positive allosteric regulator of C3 affinity at FFA2.
The ability of varying concentrations of C3, AZ1729, 4-CMTB, and compound
1 to compete with [3H]GLPG0974 in equilibrium competition binding exper-
iments inmembranes of Flp-InTM T-RExTM 293 cells induced to express hFFA2
is shown (A). The effect of increasing concentrations of 4-CMTB (B) or AZ1729
(C) on the ability of C3 to competewith [3H]GLPG0974binding inmembranes
expressing hFFA2 is displayed. Data are expressed as the percentage of spe-
cific [3H]GLPG0974 binding. Results represent the mean S.E. (n 6–10).
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affinity of AZ1729 for the receptor was 6.75  0.12 (Fig. 5B),
similar to the value obtained from the radioligand binding
experiments.
These experiments also demonstrated that in addition to
AZ1729 showing positive functional cooperativity in the C3
cAMP response this ligand also showed intrinsic agonist activ-
ity, confirming the data in Fig. 1B that AZ1729 acts as a full
agonist (Fig. 5B). Because we are able to estimate the affinity of
AZ1729 and 4-CMTB from the binding experiments (Fig. 4A)
the agonist activity of both of these allostericmodulators can be
analyzed by fitting the cAMP concentration-response curves
(Figs. 1B and 5B) to the operational model to generate a mea-
sure of the transduction efficacy (). Using this approach
AZ1729 had a  5.77 1.22 comparedwith a  value of 1.62
1.22 for 4-CMTB, indicating that AZ1729 drives stronger cou-
pling of FFA2 to the cAMP signaling pathway than the PAM-
agonist 4-CMTB.
AZ1729 Is a Functional Negative Allosteric Modulator in
hFFA2-mediated Gq/G11 Signaling—Although lacking direct
agonism, we next assessed whether AZ1729 also displayed pos-
itive cooperativity in the Gq/G11-dependent IP1 accumulation
assay. First, we assayed 4-CMTB, which has already been
reported as a PAM in other Gq/G11-dependent assays (18).
Herein 4-CMTB acted as an agonistic PAM of C3 with  
13.88 and estimated affinity (pKB) 5.47 0.20 (Fig. 5C). Sur-
prisingly, in the same assay AZ1729 acted instead as an insur-
mountable/allosteric antagonist, as it was able to reduce C3
maximal efficacy in a concentration-dependent manner, with
no significant changes inC3 affinity (Fig. 5D). Estimated affinity
for AZ1729 in this assay was 6.12 0.12 (Fig. 5D).
The ability of AZ1729 to act as a PAM in Gi-coupled FFA2
assays but as an insurmountable/allosteric antagonist in
Gq/G11-mediated FFA2 end points was further assessed in the
phospho-ERK1/2 assay. As noted earlier (Fig. 2B), at FFA2, C3
causes accumulation of phospho-ERK1/2 mainly through acti-
vation of Gq/G11. Increasing concentrations of AZ1729, as well
as displaying weak partial agonism, were able to induce a neg-
ative effect onC3maximal efficacy (Fig. 6A). To understand the
contribution of FFA2-mediated Gi versus Gq/G11 signaling,
cells were pre-treated with PTX or FR900359. After pre-treat-
ment with PTX to ablate Gi-mediated signaling and allow
detection only of Gq/G11-mediated signals, AZ1729 retained its
ability to induce a decrease in the maximal efficacy of the C3
concentration-response curve, but lost its own intrinsic partial
agonism (Fig. 6B). By contrast, in FR900359-pretreated cells,
and therefore examining only Gi-mediated links to this end
point, AZ1729 did not show any negative effect on the C3 con-
centration-response curve, but it rather behaved as an agonistic
PAM, causing an increase in affinity ofC3 anddisplaying intrin-
sic partial agonism (Fig. 6, C and D). Again these data confirm
the functional bias effect of AZ1729 at hFFA2, behaving as an
agonistic PAM in Gi-mediated signaling but as a negative
allosteric/insurmountable antagonist in Gq/G11-mediated
signaling.
AZ1729 Displays Probe Dependence at hFFA2—A common
feature of allosteric modulators is that they may display “probe
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dependence,” i.e. that the characteristics of the allosteric mod-
ulation can vary with the identity of the orthosteric agonist
examined (27–29). Because compound 1, the most potent
orthosteric FFA2 agonist yet described (15), is both substan-
tially larger, and chemically distinct, from the endogenous ago-
nists, we next assessed whether the differential effects of
AZ1729 in pathways mediated by distinct G protein subtypes
were preserved when using compound 1. To test this, increas-
ing concentrations of AZ1729were assayed together with com-
pound 1 in both cAMP and IP1 assays. As with C3, AZ1729 was
able to increase, in a concentration-dependent manner, the
observed potency of compound 1 to regulate forskolin-induced
cAMP accumulation (Fig. 7A). Application of allosteric param-
eter fitting models resulted in an apparent pKB value of 8.39
0.11 and with the ligands displaying positive net cooperativity,
 12.09. The high affinity value obtained in this experiment
prompted us to assess whether AZ1729 would display a similar
value also in a three-way radioligand binding experiment in the
presence of compound 1. AZ1729 was able to strongly, and in a
concentration-dependent manner, induce a leftward shift of
the ability of compound 1 to compete with [3H]GLPG0974 for
binding, with a maximum 100-fold increase in compound 1
affinity in the presence of 10 M AZ1729 (Fig. 7B). Application
of the allosteric ternary complexmodel equation resulted in  
47.29  0.12 and pKB  6.51  0.13, defining that AZ1729
shows a higher cooperativity value toward compound 1 than
toward C3.We next tested the effect of AZ1729 in the Gq/G11-
dependent IP1 assay. AZ1729 also caused a decrease in themax-
imal efficacy of compound 1 (Fig. 7C). Together, these results
suggest that AZ1729, at least for compound 1, preserves its bias
effect at FFA2. However, AZ1729 does display some probe
dependence, having a higher cooperativity factor for com-
pound 1 than for C3.
AZ1729 Displays FFA2 Species Ortholog-dependent Effects—
Murine models often represent appropriate systems to test
potential physiological effects of compounds. Mouse adi-
pocytes reportedly express FFA2, and activation of this recep-
tor has been demonstrated to inhibit lipolysis (30, 31). How-
ever, differences in ligand function between FFA2 species
orthologs have been reported (14) and these might limit trans-
lational interpretation of outcomes in such models. As such
AZ1729 was next assessed in both Gi- and Gq/G11-dependent
assays in Flp-InTM T-RExTM 293 cells that were able to express
mouse (m)FFA2-eYFP. In the cAMP assay, AZ1729 acted as an
agonist with an efficacy similar to that displayed by C3 andwith
potency of 6.16 0.12, significantly higher than C3 (p 0.01)
(Fig. 8A). Again, in the IP1 assay AZ1729 did not show any
direct effect (Fig. 8B), confirming the bias behavior of this com-
pound also at the mouse ortholog of FFA2.
We then moved to test whether the allosteric effects of
AZ1729 were also retained at mFFA2. In cAMP accumulation
experiments, co-addition of AZ1729 with C3 resulted in a
concentration-dependent increase of C3 potency, suggesting
thatAZ1729 also acted as an agonistic PAMatmFFA2 (Fig. 8C).
Application of the allosteric model equation resulted in an esti-
mated pKB value of 7.17  0.11 and a net cooperativity factor
 13.49. In IP1 accumulation assays, AZ1729, although dis-
playing no direct effect, was in this case able to induce a small
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increase in the potency of the C3 concentration-response curve
(Fig. 8D) with a net cooperativity factor   20.01 and an
estimated pKB value of 4.95 0.29. Together these data suggest
that, as for hFFA2, AZ1729 acts as allosteric agonist in Gi-cou-
pled end points. However, by contrast, the observed antago-
nism in Gq/G11-coupled assays at hFFA2was absent inmFFA2.
AZ1729 Induces Inhibition of Isoproterenol-induced Lipolysis
inMouseAdipocytes—Having established thatAZ1729 isGi-bi-
ased we wanted to use this ligand to define the physiological
signaling pathways employed by FFA2 in cells endogenously
expressing FFA2. As previously stated, primary mouse adi-
pocytes express FFA2, and activation of this receptor with
SCFAs has been shown to inhibit lipolysis via amechanism that
is mainly Gi-mediated (30, 31). Initially, we tested the expres-
sion levels of mFFA2 at different stages of differentiation in
such primary cultures. Differentiation was monitored by mea-
suring Ppar, Cebpa, and Fabp4 mRNA expression levels (Fig.
9A). In parallel, mFFA2 mRNA levels increased with adipocyte
differentiation, with significantly higher levels at days 6 and 8 of
the differentiation protocol (Fig. 9A). By contrast, mRNA cor-
responding to the closely related SCFA receptor FFA3 was not
detected in these primary murine adipocytes at any stage of
differentiation (data not shown). We then tested the ability of
the-adrenoreceptor agonist, isoproterenol, to induce lipolysis
in these cells, with the effect being measured by quantifica-
tion of glycerol release. Isoproterenol induced a concentra-
tion-dependent release of glycerol, with pEC50 8.49 0.18
(Fig. 9B), similar to that reported previously (32). C3
decreased isoproterenol-induced glycerol release (pEC50 
3.07  0.18) (Fig. 9C), also as reported previously (31). Sim-
ilarly, AZ1729 was able to produce concentration-depen-
dent (pEC50  5.03  0.44) inhibition of the lipolytic effect
of isoproterenol (Fig. 9C). To define whether these effects of
both C3 and AZ1729 were Gi-mediated, primary mouse adi-
pocytes were pre-treated with PTX. The effects of both C3
and AZ1729 were completely abolished when Gi protein
activity was blocked by PTX pre-treatment (Fig. 9D).
AZ1729 Induces Migration of Human Neutrophils—The
presence of FFA2 has been reported in cells of the innate
immune system, where its expression is particularly marked in
neutrophils (33–35). In these cells, FFA2 plays a role in che-
motaxis, with a mechanism that seems to be PTX-sensitive, at
least in mouse-derived neutrophils (36). We therefore assayed
the effect of AZ1729 in human neutrophils. First we assessed
that the isolated cells were positive for CD15, a marker for neu-
trophils. Results show that 98.8% of cells were indeed positive
for this marker (Fig. 10A). Next we tested whether the isolated
human neutrophils were able tomigrate toward thewell known
chemoattractant, N-formyl-methionyl-leucyl-phenylalanine
(fMLP). Results show that human neutrophils were able to
migrate toward a concentration-gradient of fMLP (Fig. 10B),
producing a standard “bell-shaped” response (37)withmaximal
migration induced by 10 nM fMLP. Both C3 and AZ1729 were
also significantly able to induce neutrophil migration at 10 mM
and 3–10 M, respectively, although to a lesser extent than 10
nM fMLP (Fig. 10C). Because in the in vitro experiments
AZ1729 behaved as an allosteric agonist in Gi-dependent
assays, we assessed the effect of AZ1729 on C3-mediated neu-
trophil migration. Neutrophil migration induced by 1 mM C3
significantly increased in the presence of 1 M AZ1729, a con-
centration of the allosteric regulator that was unable to pro-
mote significant neutrophil migration when added alone (Fig.
10D), indicating that AZ1729 can potentiate the effect of C3 on
neutrophil migration.
AZ1729 Does Not Regulate FFA2-mediated Release of GLP-1
fromMouse Colonic Crypts—Production of colonic crypts from
wild typemice alloweddemonstration thatC3 increased release
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ofGLP-1, and did so in a concentration-dependent fashion (Fig.
11A). This ability of C3 was unaffected by pre-treatment with
PTXbut completely blocked by addition of FR900359 (Fig. 11,B
andC), indicating this to be aGq/G11-mediated effect. As antic-
ipated, C3 did not mediate GLP-1 secretion in preparations
derived from Ffar2 knock-out animals (Fig. 11D). Consistent
with this being a Gq/G11-mediated pathway and the very lim-
ited effect of AZ1729 observed on Gq/G11-mediated signaling
in cells heterologously transfected to express mouse FFA2, at
concentrations of 1M, AZ1729 did not affect GLP-1 release in
mouse colonic crypts (Fig. 11E). Similarly, AZ1729 did not
affect C3-mediated GLP-1 release (Fig. 11F).
Discussion
Ligand bias, which is the ability of a compound to selectively
promote transduction of information from a receptor via a sub-
set of the panoply of signaling pathways the receptor can engage
with, comparedwith the effects produced at the same pathways
by a reference compound, is now well established and widely
discussed (38–40). Initially, studies on ligand bias focused pri-
marily on proof-of-concept and were frequently limited to
experiments performed using receptors expressed in heterolo-
gous cell systems.However, experience derived from such stud-
ies has facilitated the translation of these ideas to native sys-
tems, to the extent that clinical trials on biased ligands for a
number of receptors have been performed and more are ongo-
ing (41–43). These are designed to deliver new medicines with
high efficacy but with a significant reduction in side effects that
reflect engagement with signaling pathways that are contrain-
dicated in effective treatment. Inmany cases assessment of bias
at GPCRs has focused largely on separation of the effectiveness
of ligands to regulate signals that reflect either “canonical” G
protein-dependent or “non-canonical,” non-G protein-depen-
dent effects. The non-G protein-dependent effects are rou-
tinely assessed as interactions with arrestins, in part because a
variety of assays allow easy measurement of such interactions
but, also in part, because it is clear that arrestins allow both
kinetically and spatially distinct signals to be developed after
ligand engagement with aGPCR (44, 45). Despite this, it is clear
that many GPCRs can interact with and signal via members of
more than one of the four broad families of heterotrimeric G
proteins. As such, ligand bias can also be generated between
activation of such G protein families. In early days such studies
centered on the ability of ligands to selectively activateGs versus
Gi-mediated pathways but in recent times the development of a
wide range of G protein subtype selective biosensors has
resulted in more global assessments of ligand and receptor bias
across the G protein family (46–49).
Initial deorphanization studies on FFA2 (then designated
GPR43) highlighted the capacity of this receptor to regulate
both Gi and Gq/G11-mediated signals when stimulated with
SCFAs (5) and subsequent work has confirmed this dual signal-
ing capacity.Moreover, until now this has also been the case for
synthetic activators of FFA2,whether binding to the orthosteric
(15) or to an allosteric (16, 18–19) site.
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AZ1729 was identified initially in a high throughput screen
designed to discover regulators of FFA2. As this compound is
devoid of a carboxylic acidmoiety, which appears to be essential
for orthosteric agonist actions at FFA2 (25), it was anticipated
to act as an allosteric regulator. This was confirmed in that
AZ1729 maintained agonist function and potency at
orthosteric binding site mutants of FFA2, was unable to effec-
tively outcompete specific binding of the FFA2 orthosteric
antagonist [3H]GLPG0974 (25) and acted as a PAMof the func-
tional potency of the SCFA C3 in cAMP assays. Each of these is
incompatible with AZ1729 acting as an orthosteric ligand. In
recent times, applying modifications of the “operational
model” of ligand function has allowed assessment of the
binding affinity of allosteric ligands to GPCRs and the degree
of cooperativity produced upon co-binding of an allosteric
and orthosteric ligand (26). Although AZ1729 was unable to
compete directly with [3H]GLPG0974 for binding to FFA2, it
did produce a marked alteration in the observed affinity of
C3 to do so. Analysis of this effect using the ACTM gener-
ated pKB 6.84  0.11 for AZ1729, and a very similar value
for binding affinity of this ligand was obtained via analysis of
the effect of AZ1729 on C3-mediated inhibition of forskolin-
stimulated cAMP levels.
As initial studies on the activity of AZ1729 focused on assays
that were PTX-sensitive and, therefore, mediated via Gi-family
Gproteins, wewere surprised that in theGq/G11-dependent IP1
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FIGURE 9.AZ1729 inhibits lipolysis in primarymouse adipocytes.Gene expression profiles of Ffar2, Ppar, Cebpa, and Fabp4 in primarymouse adipocytes
at days 1, 2, 3, 6, and 8 of differentiation (A). The effect of varying concentrations of isoproterenol on glycerol production in differentiated primary mouse
adipocytes is displayed (B). The effect of increasing concentrations of C3 andAZ1729 on 10nM isoproterenol-inducedglycerol release in differentiated primary
mouse adipocytes thatwere untreated (C) and/or hadbeenpre-treatedwith PTX (D) is shown.Data are shownas expressionof target genes relative to samples
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p 0.001 two-way analysis of variance followed by Bonferroni post hoc test (D).
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assay AZ1729 was inactive as an agonist. Therefore, we turned
to assessment of ERK1/2 phosphorylation. In Flp-InTM
T-RExTM 293 cells induced to express hFFA2, C3 produced a
large, concentration-dependent increase in phosphorylation of
these proteins, as reported previously (15, 23). This clearly
reflected an integration of Gi and Gq/G11-initiated signals
because a combination of pre-treatment with PTX and the
Gq/G11 inhibitor FR900359 was required to eliminate the effect
of C3. By contrast, AZ1729 displayed very poor efficacy in this
assay. Moreover, the modest effect of AZ1729 was unaffected
by FR900359, indicating that it was not transduced via Gq/G11,
but blocked by PTX treatment. However, AZ1729 still binds to
hFFA2 in this context and, indeed, acted rather as an insur-
mountable/allosteric antagonist of the function of C3 in the
Gq/G11-mediated IP1 assay.
Hence, our studies demonstrate that AZ1729 is an allosteric
modulator that binds to a topographically distinct site from that
of the endogenous orthosteric ligand (C3) in a manner that
selectively enhances the coupling of FFA2 to Gi-signaling path-
ways through a mechanism that primarily involves an increase
in the efficacy of the orthosteric ligand (i.e.  value) with only a
modest contributionmade through an increase in the affinity of
the orthosteric ligand (i.e. value). Remarkably, the PAMactiv-
ity of AZ1729 is selective toGi signaling becauseAZ1729 acts in
the opposite direction in the context of Gq/11 signaling, namely
decreasing the coupling efficacy of the orthosteric ligand to this
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signaling pathway. The selective nature of the PAM activity of
AZ1729 is not only useful to probe the physiologically relevant
signaling pathways downstream of FFA2 activation (as
described below) but also establishes an important general
principle that it is possible to generate PAMs to GPCRs that
selectively enhance receptor coupling to one signaling pathway
over another through a mechanism that is largely independent
of themodulation of orthosteric agonist affinity but rather cen-
tered on the modulation of agonist efficacy.
Although the capacity of FFA2 to couple to various G pro-
teins has been catalogued extensively in cell systems expressing
the receptor in a heterologous manner, there remains a lack of
information regarding FFA2-mediated signal transduction in
cells endogenously expressing this receptor (7) and the contri-
bution of differentGproteins to initiation of these signals. It has
been suggested that biased ligands, by preferentially activating
specific receptor signaling pathways, can be valuable tools to
assess the mechanistic basis of biological processes (39). Our
experiments highlight this capability of biased ligands and give
further information regarding the molecular mechanisms
underpinning FFA2-mediated physiology by exploiting the
unique pharmacology of AZ1729. In this regard, we assessed
actions of AZ1729 in primary cells expressing FFA2 endog-
enously. The selective Gi-mediated agonist effects of AZ1729
allowed prediction that because neutrophil chemotaxis toward
SCFAs is a PTX-sensitive FFA2 effect (34, 36), then AZ1729
should be functional in such assays. Indeed it was, althoughmuch
less efficacious than a maximally effective concentration of the
well characterized neutrophil chemotactic agent fMLP, AZ1729
was as effective as C3 and functioned in a concentration-depen-
dent manner. Moreover, it also acted as a PAM of the potency of
C3. A concentration of AZ1729 that was ineffective in isolation
enhanced the effect of a submaximal concentration of C3.
The molecular basis of FFA2-mediated anti-lipolytic effects
was also assessed in murine adipocytes. As anticipated from
previous work, following ex vivo “differentiation” of adipocytes
produced from mouse epididymal fat, a process that acted to
substantially up-regulate levels of FFA2mRNA, AZ1729 was as
effective, and much more potent, than C3 in inhibiting isopro-
terenol-stimulated lipolysis and release of glycerol (30–31).
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FIGURE 11.AZ1729does not regulate FFA2-mediated release ofGLP-1 frommouse colonic crypts. The effect of increasing concentrations of C3 onGLP-1
secretion in mouse colonic crypts (A). The effect of 1 mM C3 on GLP-1 secretion in mouse colonic crypts that had or had not been pretreated with PTX (B) or
FR900359 (C). The effect of 1 mM C3 on GLP-1 secretion in mouse colonic crypts derived from heterozygous (/) or knock-out (/) mice for Ffar2 (D). The
effect of AZ1729 alone (E) or in combination with 1mM C3 (F) on GLP-1 secretion inmouse colonic crypts. *, p 0.05; **, p 0.01 one-way analysis of variance
followed by Dunnett’s post hoc test (A and F). *, p 0.05 unpaired t test (B–E).
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These data confirm the ability of FFA2 to reduce lipolysis in a
Gi-dependent manner, further demonstrating the utility of
AZ1729 to identify FFA2-mediated effects that rely on Gi-me-
diated signaling in physiologically relevant cells expressing the
receptor endogenously.
In contrast to this was the lack of capacity of AZ1729 to
modulate incretin secretion. C3 is able to stimulate an incretin
effect in mouse colonic tissue and cultures (50, 51), promoting
secretion of significantly enhanced levels of GLP-1 as con-
firmed herein. This was clearly a Gq/G11-mediated effect as it
was blocked by treatment with FR900359 and not reduced by
treatment of the cells with PTX. Moreover, as anticipated for a
defined Gq/G11-mediated end point, AZ1729 was unable to
recapitulate the incretin effect of C3, further confirming that
FFA2 modulates GLP-1 secretion via a Gq/11 mechanism in
mouse colonic crypts. It is interesting to note in this regard that
compound BTI-A-404, recently described as a selective and
potent competitive inverse agonist of human FFA2/GPR43
(52), has been reported to promoteGLP-1 secretion in a human
cell line. Whether there is divergence between mouse and
human FFA2 signal transduction at this end point thus requires
further investigation. Together, these data highlight the ability
of FFA2 to engage with different signaling pathways in physio-
logical contexts as well as in transfected cell systems and shows
that FFA2 pharmacology is tissue dependent. Thus, AZ1729
could be helpful in unraveling the signaling pathways behind
the physiological roles of FFA2 and, potentially, its contribution
to pathological states.
Overall, we provide detailed characterization of a novel FFA2
receptor allosteric ligand, AZ1729, which shows the unique
property of being biased to generate functional effects only at
PTX-sensitive effects of FFA2. In conjunction with the use of
selectiveGprotein pathway inhibitors this ligand can be used to
specifyGprotein selection andwill provide novel insights to the
potential value of bias in G protein signaling in areas of FFA2
biology of potential clinical relevance.
Materials andMethods
Chemistry
All solvents and reagents were purchased from commercial
suppliers and used without further purification. Analytical
HPLC/MSwas conducted on aWaters Zevo Q-TOF orWaters
LCT Premiere mass spectrometer using an Acquity PDA
(Waters) UV detector monitoring either at (a) 210 nm with an
Acquity BEH C18 column (2.1 100 mm, 1.7 m, 0.7 ml/min
flow rate), using a gradient of 2% (v/v) acetonitrile in H2O
(ammonium carbonate buffer pH 10) to 98% (v/v) acetonitrile
in H2O or (b) 230 nm with an Acquity HSS C18 column (2.1
100 mm, 1.8 m, 0.7 ml/min flow rate), using a gradient of 2%
(v/v) acetonitrile in H2O (ammonium formate buffer pH 3) to
98% (v/v) acetonitrile in H2O. Preparative HPLC was con-
ducted using aWaters Fraction Lynx Purification System using
either (i) Xbridge Prep C18 5-mOBD19 150-mm columns.
Themobile phase usedwas varying gradients of acetonitrile and
0.1 M HCO2H buffer; flow rate at 30 ml/min. 1H NMR spectra
were generated on a Varian 300MHz, Varian 400MHz, Varian
500 MHz, or Varian 600 MHz instrument. Chemical shifts ()
are given in parts per million (ppm), with the residual solvent
signal used as a reference. NMR abbreviations are used as fol-
lows: br  broad, s  singlet, d  doublet, t  triplet, q 
quartet, mmultiplet.
Synthesis of 1-[5-(3-Aminophenyl)-4-methyl-1,3-thiazol-2-yl]
guanidine—1-[5-(3-Aminophenyl)-4-methyl-1,3-thiazol-2-
yl]guanidine was synthesized according to the procedure
described in PCT Int. Application WO 2007120096 A1
20071025 (53).
Synthesis of N-[3-(2-Carbamimidamido-4-methyl-1,3-thiazol-
5-yl)phenyl]-4-fluorobenzamide—1-[5-(3-Aminophenyl)-4-
methyl-1,3-thiazol-2-yl]guanidine (64 mg, 0.26 mmol) was dis-
solved in tetrahydrofuran (1.5 ml) and triethylamine (0.036 ml,
0.26mmol) was added followed by 4-fluorobenzoyl chloride (41.0
mg, 0.26mmol). The solutionwas stirred at room temperature for
3 h. The crudewas concentrated and dissolved inMe2SO, filtered,
andpurifiedbyHPLC,usingagradientof 5–95%acetonitrile in0.1
M HCO2H as mobile phase, to yield 62 mg (64.9%) of N-[3-(2-
carbamimidamido-4-methyl-1,3-thiazol-5-yl)phenyl]-4-fluoro-
benzamide.LC-MSm/z (ES): 370.1 1HNMR(Me2SO-d6):2.31
(s, 3H), 6.88 (br s, 3H), 7.11 (d, 1H), 7.32–7.42 (m,3H), 7.69 (d, 1H),
7.79–7.83 (m, 1H), 7.97–8.08 (m, 2H), 10.32 (s, 1H).
Other Compounds—Compound 1 was synthesized as de-
scribed previously (54). 4-CMTB was synthesized as de-
scribed previously (18).
Cell Culture
All transformed cell lines used in these experiments were
derived from Flp-InTM T-RExTM 293 cells (20) and designed to
express the desired receptor, either human or mouse FFA2, on
demand following induction with the antibiotic doxycycline
(14, 15). In all cases, the receptor construct expressed was fused
in-frame to enhanced yellow fluorescent protein (eYFP) at its
C-terminal. The cells were maintained in Dulbecco’s modified
Eagle’s medium without sodium pyruvate, supplemented with
10% (v/v) fetal bovine serum and penicillin/streptomycin mix-
ture (Sigma, Poole, Dorset, UK) in a humidified atmosphere at
37 °C containing 5% CO2. To induce receptor expression, cells
were incubated overnightwith 100 ngml1 of doxycycline. Pre-
treatments with PTX and/or FR900359 (22) were performed by
incubating cells overnight with 100 ng ml1 of PTX and/or for
30 min with 100 nM FR900359.
cAMP Assays
cAMP assays were performed using a homogeneous time-
resolved fluorescence (HTRF) cAMPdynamic kit (CisBio Bio-
assays; CisBio, Codolet, France). Cells were plated at 2000 cells/
well in low-volume 384-well plates, and inhibition of 1 M
forskolin-stimulated cAMP production was assessed following
a 30-min co-incubation with test compounds. Outputs were
measured by using a PHERAstar FS plate reader (BMGLabtech,
Aylesbury, UK).
IP1 Accumulation Assays
Were performed using a HTRF IP1 dynamic kit (CisBio
Bioassays). Cells were plated at 7500 cells/well in low-volume
384-well plates and incubated for 2 h at 37 °C with test com-
pounds. Reactions were stopped according to the manufactu-
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rer’s instructions and the signal was measured using a
PHERAstar FS plate reader.
Extracellular Signal-regulated Kinase (ERK) 1/2
Phosphorylation Assays
Assays were performed using a HTRF phospho-ERK1/2 kit
(CisBio Bioassays). Briefly, cells were plated at 70,000 cells/well
in 96-well plates and then allowed to adhere for 3–6 h. Doxy-
cycline was then added (100 ng ml1) to induce expression of
the receptor of interest, and cells were maintained in culture
overnight. Prior to the assay, cells were serum starved for 4–6
h. After this, cells were treated with test compounds and incu-
bated for 5 min at 37 °C, lysis buffer was then added and cells
were incubated on a shaker for 30 min. Phospho-ERK1/2 re-
agents were added according to the manufacturer’s instruc-
tions and signal measured using a PHERAstar FS plate reader.
Membrane Preparation
Membranes were generated from Flp-InTM T-RExTM 293
cells either non-treated or treated with doxycycline (100 ng
ml1) to induce expression of FFA2. Briefly, cells were removed
from flasks by scraping and centrifuged at 3,000 rpm for 5 min
at 4 °C. Pellets were resuspended in TE buffer (75mMTris-HCl,
5 mM EDTA, pH 7.4) containing a protease inhibitor mixture
(Roche Applied Science, West Sussex, UK) and homogenized
with a 5-ml hand-held homogenizer. This material was centri-
fuged at 1,500 rpm for 7 min at 4 °C and the supernatant was
further centrifuged at 50,000 rpm for 45min at 4 °C. The result-
ing pellet was resuspended in TE buffer and protein content
was assessed using a BCA protein assay kit (Pierce, Fisher Sci-
entific, Loughborough, UK).
Radioligand Competition and Three-way Binding Assays
Assays were carried out with 7.5 nM [3H]GLPG0974 ([3H]4-
[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-car-
bonyl]-(3-chlorobenzyl)amino]butyric acid) (25), Tris binding
buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM
EDTA, pH 7.4), and the indicated concentrations of test com-
pounds in a total assay volume of 200 l in glass tubes. Binding
was initiated by the addition of membranes (5g of protein per
well). All assays were performed at 25 °C for 2 h before termi-
nation by the addition of ice-cold phosphate-buffered saline
(PBS) and vacuum filtration through GF/C glass filters using a
24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK).
Each reaction well was washed six times with 1.2-ml aliquots of
Tris-binding buffer. The filters were allowed to dry for 2–3 h
and then placed in 3ml ofUltimaGoldTMXR (PerkinElmer Life
Sciences, Beaconsfield, UK). Radioactivity was quantified by
liquid scintillation spectrometry. Specific binding was defined
as the difference between binding detected in the presence and
absence of 10 M unlabeled GLPG0974.
[35S]GTPS Incorporation Assay
Assays (21) were carried out with reactions containing 5 g
of cell membrane proteins preincubated for 15 min at 25 °C in
assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 100 mM
NaCl, 1 mM EDTA, 1 M GDP, and 0.1% fatty acid-free bovine
serum albumin) with the indicated concentrations of ligands in
a total assay volume of 500 l in glass tubes. Reactions were
initiated by addition of [35S]GTPS (50 nCi/tube), and termi-
nated after 1 h incubation at 25 °C by rapid filtration through
GF/C glass filters using a 24-well Brandel cell harvester (Alpha
Biotech, Glasgow, UK). Unbound radioligand was removed
from the filters by three washes with ice-cold wash buffer (50
mM Tris-HCl, pH 7.4, and 10 mM MgCl2), and [35S]GTPS
binding was determined by liquid scintillation spectrometry.
Nonspecific binding was measured in the presence of 100 M
GTPS.
Data Analysis and Curve Fitting
All data presented represent mean  S.E. of at least three
independent experiments. Data analysis and curve fitting were
carried out using the GraphPad Prism software package version
5.0b.Concentration-responsedatawere fit to three-parameter sig-
moidal concentration-response curves. Three-way binding exper-
imentswere fittedusing theExtendedAllostericTernaryComplex
operational model Equation 1 described previously (26),
Y 
100	
I 	 
KA

I 	 		KAKB/	
B 	 KB	1 	 	
I
S/KI 	 	
B/KB 	 	
I
S
B/	KIKB
(Eq. 1)
where Y is the measured response, whereas KI, KA, and KB rep-
resent the equilibriumdissociation constants of the radioligand
[3H]GLPG0974, unlabeled orthosteric ligand (C3 and com-
pound 1), and allosteric modulator (AZ1729 and 4-CMTB),
respectively, with [I], [A], and [B] indicating their concentra-
tions.  is the measure of the affinity cooperativity factor
between the allosteric modulator and the radioligand
[3H]GLPG0974, whereas  is the measure of the affinity coop-
erativity factor between the allosteric modulator and unlabeled
orthosteric ligand.
For functional studies (cAMP and IP1 accumulation assays),
allosteric parameters were calculated by using the operational
model Equation 2 as described previously (18),
E 
Em	A
A	KB 	 
B 	 B
BKA
n
	
AKB 	 KAKB 	 
BKA 	 
A
B
n 	 	A
A	KB 	 
B 	 B
BKA
n
(Eq. 2)
where E is the measured response, and A and B represent the
orthosteric and allosteric ligands, respectively. In this equation,
Em is the maximal system response,  is a measure of the allos-
teric cooperativity on ligand-binding affinity, and is an empir-
ical measure of the allosteric effect on efficacy. KA and KB are
measures of the binding affinities of the orthosteric and allos-
teric ligands, respectively. The value n represents the slope fac-
tor of the transduction function, whereas the abilities of the
orthosteric and allosteric ligands to directly activate the recep-
tor are incorporated through the values A and B. To fit exper-
imental data to this equation, in all cases the systemmaximum
(Em), slope (n), andKA functions were constrained, allowing for
estimations of , , A, B, and KB. To fit the data presented in
Figs. 5D and 7C, the  value was constrained to 1 to fit data for
AZ1729 that did not perturb the potency of the allosteric
ligand, whereas Bwas set to a value of effectively 0 to fit data for
AZ1729 that did not produce any direct effect on its own.
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Animals
C57BL/6J mice purchased from Charles River (Margate,
Kent, UK) were used to derive primary mouse adipocytes.
FFAR2/ mice were generated by Deltagen (55) and back-
crossed for 4 generations onto C57BL6/J at AstraZeneca,
Mo¨lndal, Sweden. Animals were cared for in accordance with
national guidelines on animal experimentation.
Derivation of PrimaryMouse Adipocytes
Epididymal fat was collected from male mice, finely minced,
and digested in HEPES buffer (100 mM HEPES, 120 mM NaCl,
4.8 mM KCl, 127 mM CaCl2, 4.5 mM glucose, 1.5% albumin, pH
7.4) containing 0.2% collagenase II (Sigma) for 30 min at 37 °C
with rotation. After this time, digested material was filtered
through a cell strainer (70m) and incubated for 15min on ice.
Sedimented stromal-vascular fraction was then collected and
centrifuged at 1500  g for 10 min. Cells were resuspended in
DMEM (10% fetal bovine serum, 4 mM glutamine, 10 mM
HEPES, 10 g/ml of insulin, 25 g/ml of sodium ascorbate) to
1000 cells/l and seeded into 96-well plates, final volume was
150 l. Cells were maintained at 37 °C, 5% CO2. Medium was
replaced the day after cell isolation with DMEM containing 10
M rosiglitazone. Medium was subsequently replaced every
2–3 days until the day of the experiment.
Lipolysis Assay
Test compounds were prepared at the indicated concentra-
tions inHanks’ balanced salt solution containing 25mMglucose
and 2% fatty acid-free bovine albumin serum. Differentiated
primary mouse adipocytes were washed three times with
Hanks’ balanced salt solution prior to the addition of test com-
pounds. Cells were then incubated at 37 °C for 2 h and, after this
time, 50 l of cell supernatants was transferred to a 96-well
plate. Glycerol concentration in the supernatants was mea-
sured by the addition of 50 l/well of free glycerol reagent
(Sigma). Plates were then incubated at 37 °C for 5 min before
absorbance at 540 nm was measured using a Pherastar FS
microplate reader.
HumanNeutrophils
Isolation and Migration Assay—Neutrophils were isolated
from human whole blood using the MACSxpress Neutrophil
Isolation Kit according to the manufacturer’s protocol (Milte-
nyi Biotec, Bergisch Gladbach, Germany). Isolated neutrophils
were resuspended in RPMI 1640 containing 0.5% fatty acid-free
bovine serum albumin. Test compounds were prepared at the
indicated concentrations in the same buffer and added at the
bottomof a 24-well plate (Sigma). Insertswere thenmounted to
the plate and neutrophils were added (5000 cells/l). Cells were
incubated at 37 °C for 1.5 h and migrated cells were then col-
lected and counted using a hemocytometer.
Flow Cytometry—Isolated human neutrophils were incu-
bated for 30 min with CD15-FITC or isotype-FITC antibodies
(Biolegend, London, UK). Cells were analyzed with a BD
FACSCaliburTM platform (BD Biosciences) and analyses were
performed with FlowJo software (TreeStar, Eugene, OR).
Quantitative PCR
Total RNA frommouse adipocytes was prepared by cell lysis
and purification using miRNeasy micro kits (Qiagen). The
miScript Reverse Transcription Kit (Qiagen) was used for
cDNA preparation. TaqMan Gene Expression Assays (Applied
Biosystems) were used for determination of gene expression.
The expression of TATA-binding protein was used as control
and data were analyzed using an ABI7900HT machine with
SDS 2.2 software. Data are presented as RQ values (2CT)
with expression relative to endogenous control and control
sample at day 1 of differentiation.
Mouse Colonic Preparations and GLP-1 Release Assays
Murine colonic crypt cultures were prepared as previously
described (56). Briefly, the muscle layer from the colon and
rectumwas removed. The remaining tissue was washed in PBS,
chopped, and digested with 0.4 mg ml1 of collagenase XI
(Sigma) at 37 °C into cell clusters resembling crypts. Crypts
were seeded onto 24-well plates coated with Matrigel (Corn-
ing), and incubated overnight at 37 °C and 5% CO2. Experi-
ments were performed after 1 day in vitro, except for the PTX
experiments, which were performed after 2 days. Crypts were
incubated with 100 nM FR900359 for 30 min or 200 ng ml1 of
PTX for 16–18 h prior to addition of test ligands. Test ligands
were added in 138 buffer (mM: HEPES 10, NaCl 138, KCl 4.5,
NaHCO3 4.2, NaH2PO4 1.2, CaCl2 2.6, MgCl2 1.2) containing
500 kallikrein inhibitor units ml1 of aprotinin, 10 M amasta-
tin, and 0.1 mM diprotin A to inhibit breakdown of GLP-1, and
incubated for 2 h at 37 °C and 5% CO2. Supernatants were
removed, and cells were lysed using lysis buffer (50 mM Tris-
HCl, 150mMNaCl, 0.5%C24H39NaO4H2O, 1% Igepal CA-630)
containing Complete EDTA-free protease inhibitor mixture.
Secretion supernatants were centrifuged at 4 °C and 8,000 g,
and lysates at 4 °C and 21,130  g to pellet cell debris. Active
GLP-1 concentrations were determined by ELISA (Millipore).
Secretion was expressed as GLP-1 released over the 2-h incu-
bation period as a percentage of the total crypt GLP-1 content.
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